Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
Background: [18 F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation dosimetry of [18 F]UCB-H in a preclinical trial and to determine the maximum injectable dose according to guidelines for human biomedical research. The radiation dosimetry was derived by organ harvesting and dynamic micro positron emission tomography (PET) imaging in mice, and the results of both methods were compared. Methods: Twenty-four male C57BL-6 mice were injected with 6.96 ± 0.81 MBq of [18 F]UCB-H, and the biodistribution was determined by organ harvesting at 2, 5, 10, 30, 60, and 120 min (n = 4 for each time point). Dynamic microPET imaging was performed on five male C57BL-6 mice after the injection of 9.19 ± 3.40 MBq of [18 F]UCB-H. A theoretical dynamic bladder model was applied to simulate urinary excretion. Human radiation dose estimates were derived from animal data using the International Commission on Radiological Protection 103 tissue weighting factors. Results: Based on organ harvesting, the urinary bladder wall, liver and brain received the highest radiation dose with a resulting effective dose of 1.88E-02 mSv/MBq. Based on dynamic imaging an effective dose of 1.86E-02 mSv/MBq was calculated, with the urinary bladder wall and liver (brain was not in the imaging field of view) receiving the highest radiation. Conclusions: This first preclinical dosimetry study of [18 F]UCB-H showed that the tracer meets the standard criteria for radiation exposure in clinical studies. The dose-limiting organ based on US Food and Drug Administration (FDA) and European guidelines was the urinary bladder wall for FDA and the effective dose for Europe with a maximum injectable single dose of approximately 325 MBq was calculated. Although microPET imaging showed significant deviations from organ harvesting, the Pearson’s correlation coefficient between radiation dosimetry derived by either method was 0.9666.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three of the SV2A ligands were radiolabeled as [ 11 C] UCB-A [112], [ 18 F]UCB-H [113-116], and [ 11 C]UCB-J [117], and all were evaluated in nonhuman primates (NHP).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feldkamp, L. A., Davis, L. C., & Kress, J. W. (1984) · Journal of the Optical Society of America A · doi:10.1364/josaa.1.000612 · Cited by 6,319 · cited 1×
“All microCT images were reconstructed using Feldkamp’s filtered backprojection algorithm [5] with a cutoff at the Nyquist frequency and an isotropic voxel size of 100 μm.”
MethodRecommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,862
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“or in any medium, provided the original work is p binding to the neuronal synaptic vesicle protein 2A (SV2A) in the brain [1].”
BackgroundStabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,350
ICRP Publication 103, The Recommendations of the International Commission on Radiological Protection
Vetter, R. J. (2008) · Health Physics · doi:10.1097/01.hp.0000324200.73903.5b · Cited by 1,263
1990 Recommendations of the International Commission on Radiological Protection
Shapiro, B. (1992) · European Journal of Radiology · doi:10.1016/0720-048x(92)90214-t · Cited by 949
Correction for partial volume effects in PET: principle and validation.
ROUSSET, O. G., Ma, Y., & Evans, A. C. (1998) · PubMed · Cited by 919
Exact and approximate rebinning algorithms for 3-D PET data
Defrise, M., Kinahan, P. E., Townsend, D. W., Michel, C., Sibomana, M., & Newport, D. F. (1997) · IEEE Transactions on Medical Imaging · doi:10.1109/42.563660 · Cited by 758 · cited 1×
“The list-mode data were histogrammed into threedimensional (3D) sinograms by Fourier rebinning [7] and reconstructed by filtered backprojection with a ramp filter cutoff at the Nyquist frequency.”
MethodSiegel, J. A., Thomas, S. R., Stubbs, J. B., Mg, S., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., et al. (1999) · PubMed · Cited by 572
MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M., Green, A. J., Zanzonico, P. B., Frey, E. C., SNMMI MIRD Committee, Bolch, W. E., Brill, A. B., Dunphy, M., Fisher, D. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 336
Cited by
Finnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
“Recently, [(18)F]UCB-H, a high-affinity PET ligand for SV2A, was developed [73, 74].”
BackgroundSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“Consequently, using the tridimensional pharmacophore model of levetiracetam and strict analogs, new compounds were designed with the same specificity and eventually higher affinity for SV2A than the drug itself, including UCB-A, UCB-H and UCB-J; these molecules are suitable for PET radiolabeling (Mercier et al., 2014).”
BackgroundInfluentialImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Evaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85
“Dosimetry studies (11) indicated that 18F-UCB-H can be used safely in humans, and an initial human study is planned.”
BackgroundSelf-citation
Metadata
- Authors
- Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., Luxen, A., Salmon, E., Seret, A., & Plenevaux, A.
- Affiliations
- University of Liège (BE)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Plenevaux, Alain
- ORCID
- Venue
- EJNMMI Research
- Published
- 2013-05-07
- Volume
- 3
- Issue
- 1
- Pages
- 35-35
- ISSN
- 2191-219X (ISSN-L)
- PMC
- PMC3655042
- OpenAlex
- W2104845164
- Cited by
- 43
- References
- 25
- Citations by year
- 2025: 2 · 2024: 6 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 6 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 2
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- EJNMMI Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Funders
- Waalse Gewest
- European Commission (238593)
- Fonds De La Recherche Scientifique - FNRS
- Université de Liège
- UCB Pharma
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiation Dose and Imaging
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- radiation dosimetry, SV2A, tissue distribution, urinary bladder wall, effective dose, organ procurement, tissue weighting factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. https://app.cochat.ai/papers/10.1186/2191-219x-3-35
- The paper
- Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., Luxen, A., Salmon, E., Seret, A., & Plenevaux, A. (2013). Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Research. https://doi.org/10.1186/2191-219x-3-35
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.